- Scientists find that AA related mutations are common in Asian liver cancers, with Taiwan most intensely affected
- Scientists call for greater public awareness of the dangers of AA in herbal products
Singapore, 19 October 2017 – Scientists from Singapore and Taiwan have revealed a decisive link between Aristolochic Acids (AA), a natural product of some plants used in herbal remedies, and liver cancers. Using mutational signature analysis, the researchers found that liver tumours had been exposed to AA, which had mutated many genes that cause cancer.
The team, led by Professor Steven Rozen from Duke-NUS Medical School (Duke-NUS), Professor Teh Bin Tean from the National Cancer Centre Singapore (NCCS), Professor Alex Chang from John Hopkins Medicine Singapore and Professor Hsieh Sen-Yung from Chang Gung Memorial Hospital in Taiwan, first sequenced the DNA of 98 liver cancers from Taiwan. Using mutational signature analysis, they found high numbers of AA-related mutations in over three-quarters of these cancers. Mutational signatures are patterns of changes in the DNA caused by mutagens, compounds that cause cancer.
"Although we knew that there was exposure to AA in Taiwan, we were very surprised to find such a high proportion of liver cancer sufferers had exposure to AA," said Professor Hsieh.
The team then looked at publicly available data on mutations from 1,400 liver cancers from around the world. While AA is found in plants used in traditional medicine worldwide, the team found high prevalence of exposure in other parts of East and Southeast Asia (see Fig. 1).
Professor Rozen noted: "This also was an unexpected finding. We did not suspect that exposure to AA was so prevalent in so many different areas."
AA, a known mutagen, was previously implicated in kidney and urinary tract cancers in Taiwan. In this new study, the researchers confirm that AA mutations are involved in causing liver cancer as well. “This was also another surprising finding of this study,” added Professor Rozen.
Professor Teh from NCCS added, “This is a follow up study for our 2013 paper, when our team made a breakthrough in understanding the cancer-promoting action of AA in urinary tract cancer. Our new study establishes that AA is also implicated in liver cancer.”
AA is a natural compound found in Aristolochia and Asarum plants. These plants are commonly used in traditional herbal remedies for many purposes including weight loss and slimming. AA has been officially banned in Europe since 2001 and in Singapore since 2004. Some herbs that contain AA have been banned in Taiwan since 2003, and in China, the use of some, but not all, AA-containing herbs in traditional medicine is restricted. While the United States Food and Drug Administration has issued warnings about herbs containing AA, their sale is unrestricted as long as they are labelled correctly and no health claims are made.
However, the effects of such bans may take years to materialise; so it could be years before rates of AA-associated cancers fall. In addition, herbs containing AA are easily available online. To complicate matters, herbs are often bundled and sold as formulations rather than individually, and some formulations might use herbs containing AA. Furthermore, herbs containing AA are sometimes improperly labelled, making it difficult for suppliers and consumers to be certain of the constituents of multi-herb formulations.
Plants that may contain AA include Asarum plants (细辛, xì xīn), and powered xì xīn products manufactured in Taiwan and China were recalled in Singapore in 2014 because they contained AA. Other herbs that are likely to contain AA are: 马兜铃 (mǎ dōu líng), 青木香 (qīng mù xiāng). 天仙藤 (tiān xiān téng), 广防己 (guǎng fángjǐ), 关木通 (guān mù tōng), 寻骨风 (xún gǔ fēng), 朱砂莲 (zhū shā lián, also written as 朱沙莲).
As AA-containing plants and remedies are still widely available, Professor Alex Chang, noted that “public education and awareness are very important for avoiding exposure.”
The study is published in Science Translational Medicine, a publication with high scientific impact that focuses on practical medical advances. The research was supported by the Singapore Medical Research Council under its Clinician Scientist Research Grant (NMRC/CIRG/1422/2015), the Singapore Ministry of Health via the Duke-NUS Signature Research Programmes, and the Chang Gung Medical Foundation in Taiwan.
For further information, please contact:
Mr Indra Gurung
Tel: +65 6516 4956
National Cancer Centre Singapore
Ms Rachel Tan
Manager, Corporate Communications
Office: 6236 9535
Ms Gillian Tan
Senior Executive, Corporate Communications
Office: 6236 9529
About Duke-NUS Medical School Singapore
The Duke-NUS Medical School (Duke-NUS, 杜克 － 新加坡国立大学医学院) was established in 2005 as a strategic collaboration between the Duke University School of Medicine, North Carolina, USA, and the National University of Singapore (NUS). Duke-NUS offers a graduate-entry, 4-year MD (Doctor of Medicine) training programme, anchored on an innovative model of self-directed learning. The School also offers MD/PhD and PhD programmes.
Duke-NUS has five Signature Research Programmes: Cancer and Stem Cell Biology, Neuroscience and Behavioural Disorders, Emerging Infectious Diseases, Cardiovascular and Metabolic Disorders, and Health Services and Systems Research.
The collaboration between Duke-NUS and Singapore Health Services (SingHealth) has established an Academic Medical Centre to advance our joint pursuits in clinical care, research and education to transform medicine and improve lives.
For more information, please visit www.duke-nus.edu.sg
About National Cancer Centre Singapore
National Cancer Centre Singapore (NCCS) provides a holistic and multi-disciplinary approach to cancer treatment and patient care. We treat almost 70 per cent of the public sector oncology cases, and they are benefiting from the sub-specialisation of our clinical oncologists. NCCS is also accredited by the US-based Joint Commission International for its quality patient care and safety. To deliver among the best in cancer treatment and care, our clinicians work closely with our scientists who conduct robust cutting-edge clinical and translational research programmes which are internationally recognised. NCCS strives to be a global leading cancer centre, and shares its expertise and knowledge by offering training to local and overseas medical professionals. www.nccs.com.sg
Notes to Editors
|Duke-NUS Medical School||杜克 － 新加坡国立大学医学院|
|Professor Steven Rozen Cancer and Stem Cell Biology Programme Director, Duke NUS Centre for Computational Biology||罗森教授 癌症与干细胞生物学 主任计算生物学中心|
|Professor Teh Bin Tean Deputy Director (Research), National Cancer Centre Singapore Professor, Cancer and Stem Cell Programme||郑敏展教授 副院长(研究), 新加坡国立癌症中心 |
|Professor Alex Y. Chang Johns Hopkins Singapore||張元吉教授 約翰霍普金斯大學,腫瘤科教授|
|Professor Hsieh Sen-Yung Director, Gastrointestinal and Hepatobiliary Department Linkou Chang Gung Memorial Hospital ||謝森永教授 胃腸肝膽科系主任,林口長庚紀念醫院 |